CStone Pharmaceuticals Future Growth

Future criteria checks 2/6

CStone Pharmaceuticals is forecast to grow earnings and revenue by 49.9% and 34.3% per annum respectively while EPS is expected to grow by 49.2% per annum.

Key information

49.9%

Earnings growth rate

49.2%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate34.3%
Future return on equityn/a
Analyst coverage

Low

Last updated26 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:PH4 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,08669N/AN/A1
12/31/2025748-194N/AN/A1
12/31/2024569-26N/AN/A1
6/30/2024457-142-284-435N/A
3/31/2024460-255-360-512N/A
12/31/2023464-367-437-589N/A
9/30/2023472-559-487-548N/A
6/30/2023481-750-537-508N/A
3/31/2023481-827-625-559N/A
12/31/2022481-903-713-611N/A
9/30/2022454-1,205-966-841N/A
6/30/2022426-1,508-1,219-1,072N/A
3/31/2022335-1,714-1,426-1,278N/A
12/31/2021244-1,920-1,633-1,484N/A
9/30/2021681-1,622-1,241-1,103N/A
6/30/20211,118-1,324-848-722N/A
3/31/20211,079-1,272-714-615N/A
12/31/20201,039-1,221-580-508N/A
9/30/2020519-1,482-971-920N/A
6/30/2020-2-1,744-1,362-1,333N/A
3/31/2020-1-1,906-1,227-1,207N/A
12/31/2019N/A-2,069-1,091-1,081N/A
9/30/201911-1,688-907-898N/A
6/30/201912-1,246-706-699N/A
3/31/201912-858-752-745N/A
12/31/201813-470-799-791N/A
9/30/201813-336-693-679N/A
12/31/201710-107N/A-240N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PH4 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PH4 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PH4 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PH4's revenue (34.3% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: PH4's revenue (34.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PH4's Return on Equity is forecast to be high in 3 years time


Discover growth companies